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Background: The CAIRO3 and AIO 0207 trials demonstrated the efficacy of fluoropyrimidine plus bevacizumab (FPþBev)
maintenance treatment in metastatic colorectal cancer (mCRC) patients. In this individual patient data meta-analysis with updated
follow-up, we aim to provide more precise estimates of treatment effects and to identify subgroups that benefit most from
maintenance treatment or observation.
Methods: In 871 patients, randomised to FPþBev maintenance treatment or observation, we investigated whether treatment
effect was modified by sex, age, performance status, response to induction treatment, primary tumour location, number of
metastatic sites, disease stage and primary tumour resection, serum LDH, platelet count, CEA, and RAS/BRAF mutation status.
Primary end point was time to second progression after reintroduction of the induction regimen (PFS2). Secondary end points
were first progression-free survival (PFS1) and overall survival (OS).
Results: At a median follow-up of 68.5 months (IQR 54.6–87.0 months), maintenance treatment was more effective compared with
observation in PFS1 (HR 0.40(95% CI 0.34–0.47)) and PFS2 (HR 0.70(0.60–0.81)). No subgroups were identified that did not benefit
from maintenance treatment in PFS1 and PFS2; no clinically relevant subgroup effects were observed. Regarding OS, pooled
results were not significant (HR 0.91(0.78–1.05)), and the trials showed marked heterogeneity in overall treatment effect and
subgroup effects.
Conclusions: FPþBev maintenance treatment is effective in all patients, regardless of the investigated subgroups.
*Correspondence: Professor M Koopman; E-mail: m.koopman-6@umcutrecht.nl
Received 7 July 2017; revised 11 September 2017; accepted 9 October 2017
r 2017 Cancer Research UK. All rights reserved 0007 – 0920/17
FULL PAPER
Keywords: colorectal cancer; metastatic disease; maintenance treatment; clinical trials; bevacizumab
British Journal of Cancer (2017), 1–9 | doi: 10.1038/bjc.2017.382
www.bjcancer.com | DOI:10.1038/bjc.2017.382 1Advance Online Publication: 9 November 2017
The clinical outcome of patients with metastatic colorectal cancer
(mCRC) has significantly improved during the last decade, partly
due to the increased availability of targeted drugs. The addition of
bevacizumab to fluoropyrimidine-based chemotherapy has
resulted in a prolonged overall and progression-free survival, and
is considered a standard option in first-line treatment of mCRC
(Hurwitz et al, 2004; Kabbinavar et al, 2008; Saltz et al, 2008;
Tebbutt et al, 2010; Cunningham et al, 2013). Until recently, the
optimal duration of systemic therapy including bevacizumab in
first-line treatment of mCRC was not well established.
The phase 3 CAIRO3 and AIO 0207 trials showed that
maintenance treatment with fluoropyrimidine and bevacizumab is
the preferred strategy in mCRC patients with stable disease or better
after induction treatment with a fluoropyrimidine, oxaliplatin and
bevacizumab, as it maintains disease control and quality of life
without relevant toxicity (Hegewisch-Becker et al, 2015; Simkens
et al, 2015; Quidde et al, 2016). However, not all patients may benefit
from this strategy. The ability to identify subgroups of patients in
which a treatment break is safe and on the other hand those in
which continuous treatment is prerequisite for better survival, would
improve clinical decision-making and reduce therapy costs.
In this individual patient data (IPD) meta-analysis of the
CAIRO3 and AIO 0207 trials with updated follow-up, we aim to
provide more precise estimates of treatment effects regarding the
use of fluoropyrimidine plus bevacizumab maintenance treatment
after induction treatment with combination chemotherapy and
bevacizumab. In addition, we aim to identify patient subgroups
according to clinical and pathological characteristics that benefit
most from fluoropyrimidine and bevacizumab maintenance
treatment or observation.
MATERIALS AND METHODS
Study design and participants. This analysis is based on the
individual patient data from two open-label, randomised phase 3
trials on maintenance treatment vs observation in first-line
treatment of mCRC: CAIRO3 (NCT00442637) and AIO 0207
(NCT00973609)(Hegewisch-Becker et al, 2015, Simkens et al,
2015). The CAIRO3 study, a superiority trial done by the Dutch
Colorectal Cancer Group, was conducted in 64 hospitals in The
Netherlands between 30 May 2007 and 15 October 2012. The AIO
0207 study, a non-inferiority trial conducted by the AIO Studien
gGmbH, enrolled patients from 106 institutions (55 hospitals and
51 private practices) in Germany between 17 September 2009 and
21 February 2013. Detailed eligibility criteria, ethical approvals,
treatment protocols and outcomes have been reported elsewhere
(Hegewisch-Becker et al, 2015; Simkens et al, 2015). In brief,
eligible patients in both trials were older than 18 years, had WHO/
ECOG performance status (PS) 0–2, histologically proven color-
ectal adenocarcinoma with distant metastases, previously untreated
for metastatic disease, with stable disease, partial or complete
response according to Response Evaluation Criteria in Solid
Tumours (RECIST, version 1.1) after induction treatment with a
fluoropyrimidine, oxaliplatin and bevacizumab.
In the two-armed CAIRO3 study, patients with stable disease or
better after 6 cycles (18 weeks) induction treatment with
capecitabine, oxaliplatin and bevacizumab (CAPOX-B) in whom
reintroduction of oxaliplatin appeared feasible were randomised
(1:1) to either observation or maintenance treatment with
capecitabine and bevacizumab (CAP-B). Patients were not enrolled
if they had experienced toxicity from the fluoropyrimidine,
oxaliplatin, or bevacizumab during induction treatment that would
prevent its safe continuation or reintroduction. Induction treat-
ment was not an integral part of the trial. Randomisation was
stratified by previous adjuvant chemotherapy (yes vs no), response
to induction treatment (stable disease vs complete or partial
response), WHO/ECOG PS (0 vs 1), serum lactate dehydrogenase
(LDH) concentrations (normal vs abnormal), and treatment centre.
In the three-armed AIO 0207 study, eligible patients were
registered prior to the start of a 24-week induction treatment with
a fluoropyrimidine (infusional fluoropyrimidine or capecitabine),
oxaliplatin and bevacizumab. The choice of a standard protocol
(i.e. FOLFOX, CAPOX-B) was left to the local investigator’s
discretion. Patients with stable disease or better and without option
for metastasectomy after 24 weeks of induction treatment were
randomised (1:1:1) to either maintenance treatment with any
fluoropyrimidine and bevacizumab, bevacizumab monotherapy, or
observation. Preliminary discontinuation of oxaliplatin or other
drugs (for example, due to toxicity) during induction treatment
was allowed. Randomisation was stratified by response to
induction treatment (stable disease vs complete or partial
response), treatment with oxaliplatin (stopped before termination
of induction treatment vs ongoing until end of induction phase),
previous adjuvant therapy (with oxaliplatin vs without oxaliplatin
vs no adjuvant treatment), and WHO/ECOG PS (0–1 vs 2).
Patients from the bevacizumab monotherapy arm were excluded
from the present analysis. All patients in both trials provided
written informed consent.
Study treatments. In the CAIRO3 study, maintenance treatment
consisted of capecitabine 625 mg m 2 orally twice daily continu-
ously, plus bevacizumab 7.5 mg kg 1 intravenously every 3 weeks.
Patients with progressive disease in either the observation or
maintenance arm were to receive reintroduction of the induction
treatment regimen, that is, CAPOX-B. Reintroduced CAPOX-B
was to be continued until progression, death, or an unacceptable
adverse event, whichever occurred first. If CAPOX-B reintroduc-
tion was not possible after all due to persisting sensory neuropathy
(grade X2) or any other reason, the treatment choice was left to
the local investigator’s discretion.
In the AIO 0207 study, randomised patients received either
continuation of a fluoropyrimidine (infusional every 2 weeks, or
capecitabine every 3 weeks in standard dosages; the fluoropyrimidine
could be switched between induction and maintenance treatment)
plus bevacizumab (7.5 mg kg 1 every 3 weeks, or 5 mg kg 1 every 2
weeks), or bevacizumab monotherapy (same dosage), or no
treatment. Maintenance treatment was continued until disease
progression, unacceptable toxicity, surgical resection, other ablative
treatment, at patient’s request, or local investigator’s decision. If either
the fluoropyrimidine or bevacizumab was discontinued before
progression, the remaining drug was continued as monotherapy in
the fluoropyrimidine plus bevacizumab arm. At first progression, all
patients were to receive reintroduction of the induction treatment
regimen (i.e., any fluoropyrimidine, oxaliplatin plus bevacizumab)
according to protocol. Reintroduction included all drug components
of the induction treatment, except for those that could not be used
due to persistent toxicity or contraindications. If reintroduction of the
induction treatment regimen was not possible for any reason, the
choice of treatment was at the local investigator’s discretion.
Outcomes. Patients in both trials were assessed for disease status
according to RECIST criteria. The primary end points in both trials
(time to second progression upon reintroduction of the induction
treatment regimen in CAIRO3, and time to failure of strategy in
AIO 0207) were comparable in definition. The primary end point
in this IPD meta-analysis was second progression-free survival
(PFS2), defined as the interval between randomisation and second
progression (for those who had a first progression) while under
treatment with reintroduction of a fluoropyrimidine, oxaliplatin
and bevacizumab, or until the beginning of another treatment
(including a new drug), death or end of trial for patients who did
not have a second progression. PFS2 was regarded as equal to first
progression-free survival (PFS1) if patients did not receive
BRITISH JOURNAL OF CANCER Maintenance treatment vs observation in mCRC
2 www.bjcancer.com | DOI:10.1038/bjc.2017.382
reintroduction of the induction regimen for any reason, or if a
valid response evaluation was not performed. Secondary end points
in both trials included time until first progression (PFS1), and
overall survival (OS). PFS1 was defined as the interval between
randomisation and first progression while under maintenance
treatment or observation, or until death or end of trial for patients
without progression. OS was defined as the time from randomisa-
tion to death from any cause or date of last follow-up, at which
point patients who were still alive were censored. Cut-off dates for
the present analysis were March 2017 for CAIRO3, and December
2016 for AIO 0207.
Statistical analysis. This pooled analysis was based on individual
patient data of the intention-to-treat population of the CAIRO3
and AIO 0207 trials, comprising all patients who were randomised
to fluoropyrimidine plus bevacizumab maintenance treatment or
observation. Patients from the bevacizumab monotherapy arm of
the AIO 0207 study were excluded from the analyses, since the
CAIRO3 study did not include this treatment option.
First, the median duration of follow-up was calculated for the
pooled study population using the reverse Kaplan–Meier method.
Survival curves were estimated with the Kaplan–Meier method and
compared with the log-rank test. Next, we performed subgroup
analyses, including the following parameters: age (o or X70 years
at randomisation), sex (male vs female), primary tumour location
(colon vs rectum or rectosigmoid), response to induction treatment
(stable disease vs complete or partial response), WHO/ECOG PS (0
vs 1–2), number of metastatic sites (1 vs 41), stage of disease and
primary tumour resection status (synchronous, resected vs
synchronous, non-resected vs metachronous disease), serum
LDH at randomisation (normal vs elevated), platelet count
(o400 vs X400 109 l 1) and serum CEA (p20
vs420 ng ml 1) at start of induction treatment, and RAS/BRAF
mutation status (RAS plus V600EBRAF wild-type vs RAS mutant vs
V600EBRAF mutant). No power, sample size, or sensitivity
calculations were done as these subgroup analyses were exploratory
in nature. We analysed overall and subgroup treatment effects
using mixed effect Cox models with study as random intercept to
take clustering of patients within studies into account, and
treatment (and any co-variables) as fixed effects to calculate
hazard ratios (HRs) and 95% confidence intervals (CIs). We
refrained from including a random treatment slope per study as
none of the models significantly improved upon such extension.
Analyses were stratified for prior adjuvant chemotherapy, response
to induction treatment, and WHO/ECOG PS, and adjusted for the
following potential confounders by including as co-variable: age,
sex, stage, primary tumour location, primary tumour resection,
number of metastatic sites, LDH at randomisation, and the interval
between primary diagnosis and randomisation. Subgroup analyses
regarding stage of disease combined with primary tumour
resection status were not adjusted for stage and primary tumour
resection. Patients with missing values in variables relevant for a
particular analysis were excluded from that analysis. Interaction
terms between treatment and each subgroup variable were used to
assess and test heterogeneity of treatment effects. Inspection of
Schoenfeld residuals showed that the proportionality of the hazard
assumption was not violated. We report nominal, two-sided
P-values (significance level set to 0.05), without taking multiple
testing into account. Statistical analyses were performed using IBM
SPSS Statistics, version 21.0 (Armonk, NY: IBM Corp) and R
version 3.0.3 (particularly library coxme version 2.2–5).
RESULTS
Patients. By pooling individual patient data from both trials,
including both treatment arms of CAIRO3 and two out of three
CAIRO3 AIO 0207
852 assessed for eligibility
825 eligible and started induction
472 randomised558 randomised
278 received fluoropyrimidine




monotherapy 158 received no treatment
278 assessed for primary
efficacy analysis
(intention-to-treat population)
434 in maintenance group
included in IPD meta-analysis
437 in observation group
included in IPD meta-analysis
279 assessed for primary
efficacy analysis
(intention-to-treat population)
147 assessed for PFS1 and
PFS2 analysis
156 assessed for OS analysis
153 assessed for PFS1 and
PFS2 analysis
156 assessed for OS analysis
154 assessed for PFS1 and
PFS2 analysis










More than one reason could
be reported
Figure 1. Trial profiles for CAIRO3 and AIO 0207. IPD = individual patient data; OS = overall survival; PFS1 = first progression-free survival;
PFS2 = second progression-free survival.
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treatment arms of AIO 0207, we obtained data of 871 patients: 437
assigned to the observation group and 434 assigned to the
fluoropyrimidine plus bevacizumab maintenance treatment group
(Figure 1). Patient characteristics were comparable between
treatment groups, except for a higher percentage of patients with
age X70 years in the observation group (Table 1). Differences in
overall patient characteristics between CAIRO3 and AIO 0207
(bevacizumab monotherapy arm excluded) were found regarding
WHO/ECOG PS, prior adjuvant chemotherapy, primary tumour
location, stage of disease combined with primary tumour resection
status, and serum LDH at randomisation (Supplementary Table 1).
Efficacy. Median follow-up time for all patients was 68.5 months
(IQR 54.6–87.0 months). Overall, there was a significant benefit
from maintenance treatment compared with observation for PFS1
(HR 0.40 (95% CI 0.34–0.47)) and the primary end point PFS2
(HR 0.70 (0.60–0.81)). The benefit of maintenance treatment was
observed in all subgroups that were investigated (Figures 2 and 3),
although for patients with metachronous disease this was non-
significant in PFS2 (at a nominal P-value for significance of 0.05).
In particular, primary tumour location was not predictive of the
benefit of maintenance treatment or observation. Patients with
elevated compared to normal platelet count at start of induction
treatment showed a significant interaction in favour of main-
tenance treatment regarding PFS1 (HR 0.32 (95% CI 0.24–0.42) vs
HR 0.45 (0.37–0.55), nominal P-value for interaction
(Pinteraction)¼ 0.042), and PFS2 (HR 0.55 (95% CI 0.42–0.72) vs
HR 0.77 (0.64–0.93), nominal Pinteraction¼ 0.040), respectively.
Supplementary Table 2 shows efficacy outcomes in the pooled
study population and individual studies for PFS1 and PFS2.
Supplementary Tables 3 and 4 show individual study results
regarding subgroup analyses for PFS1 and PFS2.
Overall treatment effect in OS did not reach statistical
significance, neither in the individual trials, nor when the data
were pooled (HR 0.91 (95% CI 0.78–1.05))(Figure 4). In fact,
overall treatment effect for OS was significantly different between
the two trials (likelihood ratio P-value¼ 0.008). While main-
tenance treatment versus observation resulted in a clinically
relevant increase in median OS in CAIRO3, this was not observed
in AIO 0207 (Supplementary Table 2). Subgroup analyses for OS
showed a marked heterogeneity with opposite results between the
two trials (Supplementary Table 5). Despite this, the combined
data suggested that maintenance treatment improved OS for
female sex (nominal Pinteraction¼ 0.003) and complete or partial
response as best response on induction treatment (nominal
Pinteraction¼ 0.035)(Figure 4).
Treatment upon first progression. After first progression, 407
(47%) of 871 patients underwent reintroduction of the induction
treatment regimen. Out of these 407 patients, 377 (93%) received
reintroduction of all components, that is, fluoropyrimidine,
oxaliplatin and bevacizumab. The percentage of patients that
underwent reintroduction according to protocol was significantly
lower in the fluoropyrimidine plus bevacizumab group compared
with the observation group (165 out of 429 (38%) vs 242 out of 437
(55%), respectively, Po0.001). The percentage of patients that
received reintroduction of the induction treatment regimen was
significantly higher in CAIRO3 compared with AIO 0207 (304 out
of 557 (54%) vs 103 out of 309 (33%), respectively, Po0.001).
Subsequent therapies received during the course of metastatic
disease were comparable between the two trials and within treatment
groups, although anti-EGFR therapy was more frequently received
by patients in AIO 0207 compared with CAIRO3 (84 out of 314
(27%) vs 102 out of 557 (18%), respectively; Table 2).
DISCUSSION
This IPD meta-analysis of the CAIRO3 and AIO 0207 trials with
updated follow-up confirms the benefit of fluoropyrimidine plus
bevacizumab maintenance treatment compared with observation
in first-line treatment of mCRC. Despite differences in the study
design of CAIRO3 and AIO 0207, our pooled results show that
fluoropyrimidine plus bevacizumab maintenance treatment is
more effective compared with no treatment for PFS1 and the
primary end point PFS2, regardless of the investigated subgroups.
By using individual patient data, this pooled analysis distin-
guishes itself from study-level meta-analyses (Berry et al, 2015;
Pereira et al, 2015; Stein et al, 2016; Zhao et al, 2016). Our pooled
subgroup analyses provide the best available evidence on predictors
of response to fluoropyrimidine and bevacizumab maintenance
treatment compared with observation thus far. All investigated
subgroups showed a significant benefit from maintenance treat-
ment regarding PFS1 and PFS2, except for patients with






CAIRO3 279 (64) 278 (64)
AIO 0207 158 (36) 156 (36)
Age
X70 130 (30) 101 (23)
Sex
Male 278 (64) 288 (66)
WHO/ECOG performance status
0 236 (56) 249 (59)
1 178 (42) 170 (40)
2 11 (3) 5 (1)
Best response to induction treatment
Complete or partial response (CR/PR) 290 (66) 282 (65)
Stable disease (SD) 147 (34) 152 (35)
Prior adjuvant chemotherapy
Yes 111 (25) 112 (26)
Site primary tumour
Colon 244 (56) 236 (54)
Rectum 134 (31) 138 (32)
Rectosigmoid 59 (14) 60 (14)
Number of metastatic sites
1 171 (41) 188 (44)
41 249 (59) 235 (56)
Stage of disease and primary tumour resection status
Synchronous,a resection 171 (39) 182 (42)
Synchronous, no resection 154 (35) 163 (38)
Metachronous 112 (26) 89 (21)
LDH elevated at randomisation
Yes 212 (50) 224 (54)
Platelets at start induction treatment
o400 109 l1 265 (65) 287 (70)
X400 109 l1 144 (35) 122 (30)
CEA at start induction treatment
p20 ng ml1 121 (35) 142 (41)
420 ng ml 1 227 (65) 208 (59)
RAS/BRAF mutation status
RAS / V600EBRAF wild-type 110 (34) 129 (40)
RAS mutant 189 (59) 167 (52)
V600EBRAF mutant 22 (7) 23 (7)
Abbreviations: Bev¼bevacizumab; FP¼ fluoropyrimidine. The data are n (%) unless
otherwise stated. Due to rounding, not all percentages total 100.
aSynchronous disease was defined as distant metastases discovered p6 months of the
primary CRC diagnosis.
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metachronous disease in PFS2. The latter may be partly due to the
small number of patients with metachronous disease assigned to
maintenance treatment (n¼ 76). Another possible explanation
could be a (partial) chemoresistance due to previous adjuvant
treatment (Mekenkamp et al, 2010), since 108 out of 201 patients
(54%) with metachronous disease received prior adjuvant che-
motherapy. There is growing evidence that primary tumour
sidedness (right colon: caecum-transverse colon; left colon: splenic
flexure-rectum) influences prognosis and therapy response in
mCRC patients (Petrelli et al, 2016; Holch et al, 2017). Although
the specific data on sidedness were lacking in the present analysis,
our findings do not suggest a predictive role of primary tumour
location (colon vs rectosigmoid or rectum) for the benefit of
maintenance treatment or observation. Patients with elevated
compared to normal platelet count at start of induction treatment
showed a significant interaction in favour of maintenance
treatment regarding PFS1 and PFS2. Given the exploratory nature
of our subgroup analyses, these findings do not allow definitive
conclusions. Nonetheless, our results are in line with the MRC
COIN trial, which previously showed that patients with elevated
baseline platelet count had inferior survival and quality of life with
intermittent chemotherapy, and should therefore not receive a
treatment break (Adams et al, 2011).
Regarding OS, it should be noted that both trials were not
designed or powered to show a difference in this end point. Overall
treatment effect for OS differed significantly between CAIRO3 and
AIO 0207, which limits the credibility of subgroup analyses
regarding this end point. There was no significant difference in
overall treatment effect when data were pooled. Although
subgroup analyses for OS showed a marked heterogeneity between
the two trials, significant interactions with OS and maintenance
treatment were observed for females, and patients with complete or
partial response as best response to induction treatment. The latter
subgroup was also a significant predictor for the effect size of
maintenance treatment in OS in the initial subgroup analyses of
CAIRO3 (Simkens et al, 2015). This may be partly explained by the
fact that pooled OS results were more influenced by CAIRO3 due
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Figure 2. Forest plot showing adjusted treatment effects for PFS1 in subgroups with P-values for heterogeneity across subgroups. Analyses
were performed using a mixed effect Cox model with study as random intercept and treatment (and any co-variables) as fixed effects. Subgroup
analyses were stratified for prior adjuvant chemotherapy, response to induction treatment, WHO/ECOG PS, and adjusted for age, sex, stage,
primary tumour location, primary tumour resection, number of metastatic sites, LDH at randomisation, and interval between primary diagnosis and
randomisation. Subgroup analyses for ‘stage of disease and primary tumour resection status’ were not adjusted for stage and primary tumour
resection. CR/PR¼ complete or partial response; SD¼ stable disease.
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There are several reasons that could explain the diverging
overall treatment effect in OS between CAIRO3 and AIO 0207. For
instance, OS can be highly influenced by subsequent treatment
lines (Shi et al, 2015). In our analysis, therapies received during
subsequent treatment lines were comparable between both trials,
except for a higher rate of patients that received anti-EGFR therapy
in AIO 0207 compared with CAIRO3. The data on systematic
differences in the sequence of agents used or in the total number of
agents received were beyond the scope of the present analysis, since
the data are likely to be too limited for a proper investigation on
the impact of these differences. Furthermore, several important
differences exist between CAIRO3 and AIO 0207 regarding patient
registration (after vs before start induction therapy), fluoropyr-
imidine maintenance protocols (capecitabine vs any fluoropyrimi-
dine), duration of induction treatment (18 vs 24 weeks), and
exclusion of patients who experienced toxicity from oxaliplatin
during induction treatment that precluded reintroduction of this
agent (yes vs no). These differences in study designs, together with
varying study populations, could have influenced treatment
outcomes, especially regarding OS.
The rate of reintroduction according to protocol was signifi-
cantly higher in CAIRO3 (54%) compared with AIO 0207 (33%).
This is likely to be related to the exclusion of patients who were not
eligible for oxaliplatin reintroduction in CAIRO3. It may also be
related to a higher cumulative oxaliplatin dose resulting from the
longer induction period in AIO 0207, suggesting that a 24-week
induction period may be too long. These differences between
CAIRO3 and AIO 0207 in number of cycles and cumulative doses
administered during the induction and reintroduction phase may
have influenced OS outcomes.
Our findings support the ESMO consensus guidelines recom-
mendation that a combination of a fluoropyrimidine plus
bevacizumab is the optimal maintenance treatment following
induction treatment with fluoropyrimidine, oxaliplatin and
bevacizumab (Van Cutsem et al, 2016). Our results suggest that
both patients with poor prognostic characteristics and patients
with favourable prognostic characteristics derive a significant
benefit from maintenance treatment. Clearly, alternative outcome
measures and factors should be considered in the treatment
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RAS mutant
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Overall
HR maintenance vs observation
Figure 3. Forest plot showing adjusted treatment effects for PFS2 in subgroups with P-values for heterogeneity across subgroups. Analyses
were performed using a mixed effect Cox model with study as random intercept and treatment (and any co-variables) as fixed effects. Subgroup
analyses were stratified for prior adjuvant chemotherapy, response to induction treatment, WHO/ECOG PS, and adjusted for age, sex, stage,
primary tumour location, primary tumour resection, number of metastatic sites, LDH at randomisation, and interval between primary diagnosis and
randomisation. Subgroup analyses for ‘stage of disease and primary tumour resection status’ were not adjusted for stage and primary tumour
resection. CR/PR¼ complete or partial response; SD¼ stable disease.
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patient’s cultural and social preferences. Although inclusion of
QoL measures in this IPD meta-analysis was difficult due to
differences in time points of assessment and compliance rates, the
individual trials reported comparable findings in the QoL
analyses. Both trials showed that active maintenance treatment
was not associated with a detrimental effect on QoL when
compared with no treatment (Simkens et al, 2015; Quidde
et al, 2016). Most importantly, treatment decisions should be
individualised after a thorough discussion with the patient. This
should include discussion of the estimated survival time, time free
from cancer-related symptoms, side-effects and treatment con-
straints, and the impact on career and family life (social and
financial), as stated in the ESMO consensus guidelines (Van
Cutsem et al, 2016).
In conclusion, this IPD meta-analysis shows that fluoropyr-
imidine plus bevacizumab maintenance treatment is effective in
mCRC patients with stable disease or better after induction
treatment with a fluoropyrimidine, oxaliplatin, and bevacizumab,
with a significant benefit in PFS1 and PFS2. Subgroup analyses did
not identify any subpopulations that derived comparable benefit
from observation after induction treatment.
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Figure 4. Forest plots showing adjusted treatment effects for OS in subgroups with P-values for heterogeneity across subgroups. Analyses were
performed using a mixed effect Cox model with study as random intercept and treatment (and any co-variables) as fixed effects. Subgroup
analyses were stratified for prior adjuvant chemotherapy, response to induction treatment, WHO/ECOG PS, and adjusted for age, sex, stage,
primary tumour location, primary tumour resection, number of metastatic sites, LDH at randomisation, and interval between primary diagnosis and
randomisation. Subgroup analyses for ‘stage of disease and primary tumour resection status’ were not adjusted for stage and primary tumour
resection. CR/PR¼ complete or partial response. SD¼ stable disease.
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